Hemochromatosis (Iron Overload) Disease Treatment Market Projected at $33.11 Billion by 2029 | Strategic Insights and Forecast Data
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Hemochromatosis (Iron Overload) Disease Treatment Market Size Changed, over the years?
The market size for the treatment of hemochromatosis (iron overload) has been on a consistent growth trajectory in the past few years. It is expected to expand from a value of $27.91 billion in 2024 to $28.73 billion in 2025, yielding a compound annual growth rate (CAGR) of 2.9%. The historical growth can be attributed to factors such as heightened clinical awareness and diagnosis, advancements in therapy, genetic screening, early detection, the prevalence of hereditary hemochromatosis, as well as ongoing research and clinical trials.
How Much Will the Hemochromatosis (Iron Overload) Disease Treatment Market Be Worth in 2029?
The market size for treating hemochromatosis (iron overload) disease is predicted to experience consistent expansion in the following years, escalating to a value of $33.11 billion in 2029 with a compound annual growth rate (CAGR) of 3.6%. The predicted upsurge during the projection period can be credited to a shift towards personalized medicinal practices, progress in therapeutic innovations, enhanced screening and awareness movements, collaborations in genetic studies, and international health measures. Noteworthy trends to observe during this period encompass concentration on patient consciousness and knowledge, investigation of genetic and molecular therapy options, the utilization of telemedicine and remote patient monitoring services, the inclusion of digital health platforms, and the worldwide enlargement of treatment accessibility.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13151&type=smp
Which is the Largest Company in the Hemochromatosis (Iron Overload) Disease Treatment Market?
Major companies operating in the hemochromatosis (iron overload) disease treatment market report are Pfizer Inc., AbbVie Inc., Novartis AG, Fresenius Kabi AG, Abbott Laboratories, Merck KGaA, Laboratory Corporation, Quest Diagnostics, Chiesi Farmaceutici S.p.A., Apotex Inc., Shire PLC, CSL Vifor, ARUP Laboratories, Myriad Genetics Inc., Fulgent Genetics, Ionis Pharmaceuticals Inc., Invitae Corp., Abcam plc., GeneDx, Ambry Genetics, La Jolla Pharmaceutical Company, Silence Therapeutics, PreventionGenetics, DisperSol Technologies LLC., Hinoman Ltd.
What Are the Main Market Drivers in the Hemochromatosis (Iron Overload) Disease Treatment Industry?
The rise in anemia cases is predicted to enhance the expansion of the hemochromatosis (iron overload) disease treatment market. Anemia, a blood-related disorder, signifies a decline in red blood cell count or hemoglobin content, resulting in the blood’s lack of capacity to deliver oxygen to various body organs and tissues. Hemochromatosis (iron overload) disease treatment is designed to inhibit anemia using iron chelator medications that avert organ damage and complications tied to blood disorders. For example, as of December 2023, World Health Organization (WHO), based in Switzerland, stated approximately 40% of children between 6-59 months, 37% of pregnant females and 30% of women from 15 to 49 globally have been diagnosed with anemia. Consequently, the rising incidence of anemia is likely to stimulate the growth of the hemochromatosis (iron overload) disease treatment market. The continuing rise in stressful lifestyles is also anticipated to boost the growth of the hemochromatosis (iron overload) disease treatment market. High-stress levels in daily life can severely affect an individual’s physical and emotional health, potentially leading to various health conditions, including hemochromatosis (iron overload) disease. The therapy for hemochromatosis, marked by excess iron in the body, tackles not only the physical aspects of the disease, but also has a significant part in lowering the emotional and psychological stress often linked with navigating a chronic health issue. For example, in December 2022, the American Psychiatric Association, a professional group of psychiatrists based in the US, stated that over one in four Americans (26%) anticipated higher stress levels at the onset of 2023, an increase from one in five (20%) the previous year. Consequently, an increase in a stressful lifestyle propels the hemochromatosis (iron overload) disease treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=13151&type=smp
How Is the Hemochromatosis (Iron Overload) Disease Treatment Market Segments Structured?
The hemochromatosis (iron overload) disease treatment market covered in this report is segmented –
1) By Type: Hereditary Hemochromatosis, Acquired Hemochromatosis
2) By Treatment: Therapeutic Phlebotomy, Iron Chelation Therapy, Other Treatments
3) By End-Users: Hospitals, Surgical Centers, Other End-Users
Subsegments:
1) By Hereditary Hemochromatosis: Genetic Counseling, Phlebotomy, Chelation Therapy
2) By Acquired Hemochromatosis: Treatment Of Underlying Conditions, Phlebotomy, Chelation Therapy
What Strategic Trends Are Transforming the Hemochromatosis (Iron Overload) Disease Treatment Market?
Prominent businesses in the hemochromatosis (iron overload) disease treatment market get the green light for drugs like deferiprone, intended for patients suffering from transfusional iron overload. The aim is to decrease excess iron in the system and avoid complications related to iron build-up, such as organ impairment. Deferiprone is a drug used to counteract iron overload in people who have undergone multiple blood transfusions. Such cases are often seen in conditions like thalassemia, sickle cell anemia or other persistent anemias. For example, in March 2023, Chiesi Global Rare Diseases Inc, an American company, proclaimed the endorsement of FERRIPROX MR (deferiprone) extended-release tablets in Canada. FERRIPROX MR is recommended for treating transfusional iron overload in patients with thalassemia syndromes, particularly when the current chelation treatment is insufficient. It is also effective for patients with sickle cell disease (SCD) or other forms of anemia. Deferiprone, an orally administered iron chelator, proficiently lowers the body’s iron concentration. It does so by infiltrating cell membranes, connecting to excess iron, and enabling its extraction from organs and tissues.
Access The Full Report Here:
Which Global Regions Offer the Highest Growth in the Hemochromatosis (Iron Overload) Disease Treatment Market?
North America was the largest region in the hemochromatosis (Iron Overload) disease treatment market in 2024. The regions covered in the hemochromatosis (iron overload) disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13151
This Report Delivers Insight On:
1. How big is the hemochromatosis (iron overload) disease treatment market, and how is it changing globally?
2. Who are the major companies in the hemochromatosis (iron overload) disease treatment market, and how are they performing?
3. What are the key opportunities and risks in the hemochromatosis (iron overload) disease treatment market right now?
4. Which products or customer segments are growing the most in the hemochromatosis (iron overload) disease treatment market?
5. What factors are helping or slowing down the growth of the hemochromatosis (iron overload) disease treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
